Moderna stock is rising after the company agreed to pay up to $2.25 billion to settle a patent dispute over technology used ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

Moderna Inc MRNA shares are rising in Tuesday’s after-hours session after the company announced it reached a settlement agreement with Arbutus Biopharma and Genevant Sciences. Moderna shares are ...

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s ...

Moderna (MRNA) stock rises as a $950M payment to resolve a patent dispute with Arbutus (ABUS) and Roivant (ROIV) lifts a key legal overhang. Read more here.

Moderna (MRNA) stock jumped 8.7% after announcing a $950M patent settlement with Arbutus and Genevant, the largest pharma patent deal ever recorded.

Moderna (MRNA) stock closed higher on Wednesday after the FDA reversed its earlier refusal-to-file decision on the company’s mRNA-1010 seasonal influenza vaccine. As the regulatory agency agreed to ...

Moderna, Inc. settles LNP patent dispute for $950M, securing royalty-free tech access and legal clarity; click for what it ...

Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks Dominating Today’s Market Action. Moderna snapped a two-day losing streak on Wednesday, jumping 15.99 percent to finish at $57.80 apiece after ...

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores ...